Dimethyl sulfoxide favors the emetic efficacy of lycorine in beagle dogs - a novel strategy for the treatment of poisoning.
Res Vet Sci. July 2023;160(0):11 - 17.
Ralf Regenthal1, Getu Abraham2 1 Division of Clinical Pharmacology, Rudolf Boehm Institute for Pharmacology and Toxicology, Medical Faculty, University of Leipzig, Härtelstrasse 16-18, 04107 Leipzig, Germany. Electronic address: ralf.regenthal@medizin.uni-leipzig.de.; 2 Institute of Pharmacology, Pharmacy and Toxicology, Faculty of Veterinary Medicine, University of Leipzig, An den Tierkliniken 15, 04103 Leipzig, Germany.
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Abstract
Poisoning in small animals represents an ongoing hazard and therapeutic problem in veterinary medicine. Therapeutic induction of emesis in time enables a fast elimination of a toxic compound resulting in a shortened course of poisoning and a higher safety level thereafter, which decisively improves prognosis and treatment. Lycorine is a reliable emetic drug in beagle dogs without serious side effects thought to be more beneficial in tolerability and efficacy than the rarely used apomorphine. Therefore, this study investigates efficacy and tolerability of differently composed potential drug formulations of lycorine hydrochloride for s.c. administration in dogs as an emetic principle. By emesis response analysis four dimethyl sulfoxide (DMSO)-based active pharmaceutical ingredient (API) formulations were favored. Two of them (F5 and F6) qualified for further drug development. Both formulations ensure a safe pharmacologically induced emesis within about 30 min after injection, suitable for use as an in time decontaminant in acute poisoning of dogs. DMSO-based formulations were well tolerated and offer a novel promising strategy for treatment of poisoning.
Keywords

Dog;
Drug formulation;
Emetic drug;
Lycorine;
Poisoning;
|
 |
Article Tools:
Archives Highlights:
Factors Associated with Medication Noncompliance in Dogs in New Zealand.
Medication noncompliance was recorded for 47% (71/151) of owners. Increasing dog age was associated with better owner compliance. Forty-seven percent (71/151) of owners reported that "nobody" showed them how to administer the medication. One-third of dog owners (47/151) reported challenges in medicating their pets. The most common reason cited by clients reporting challenges was a resistant pet.
|
Use of Dog Serologic Data for Improved Understanding of Coccidioidomycosis: A One Health Approach.
The overall seropositivity rate among tested dogs was 37.6%. Average test positivity rates in states with =0.5 tests per annum per 10,000 households were 35.4% (Texas) to 74.1% (Montana). For these states, average annual incidence per 10,000 households was as follows: Arizona (86.8), New Mexico (0.89), Nevada (0.78), California (0.75), Montana (0.63), Colorado (0.41), Oregon (0.41), Texas (0.38), Idaho (0.37), Wyoming (0.34), Utah (0.32), and Washington (0.26). Human incidence in California and Arizona between 2012 and 2022 was significantly correlated with dog incidence.
|
[Disease Caused by Filoviruses: An Update].
The Marburg and Ebola viruses belong to the Filoviridae family and are known to cause emerging zoonotic diseases. These viruses have a high case fatality rate and are easily transmissible from person to person, which makes them capable of triggering outbreaks, including in non-endemic regions, and are also considered agents of bioterrorism. This review aims to improve clinical knowledge and the approach to suspected cases of FD. Improved surveillance and preparedness for potential global outbreaks are essential measures to effectively respond to these public health threats and to ensure that healthcare professionals are well-informed and prepared to deal with these diseases.
|
Case series of maggot debridement therapy demonstrates safety and efficacy for treating problematic wounds in cats and dogs in Mexico.
Treatment was administered by applying 8-10 larvae per square cm surface area directly on the wound bed and covering the wound with a sterile polyester mesh, sutured to the skin. These were left on the wound for cycles of approximately 48 hours (24-72 hours); the cycles were repeated if more than 20% necrotic tissue remained after treatment. Review of these cases revealed that 80% of treated wounds achieved 100% debridement within 48-96 hours of treatment.
|
Effective treatment with afoxolaner (NexGard) of Trixacarus caviae in a pet guinea pig.
The animal was treated with a single oral dose of 2.50 mg/kg afoxolaner, and the lesions, presence/absence of mites, and intensity of pruritus were evaluated periodically until 2 months post-treatment. A week after the medication, the lesions were milder, but pruritus was still present and was attributed to the healing process. Further examinations showed significant improvement with the complete remission of clinical signs and no mites at the microscopic examination after 4 weeks.
|
|